Trevi Therapeutics
195 Church Street
• 14th Floor
• New Haven, CT 06510
US
Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.
Categories
1 WalletHub, 2022; 2 WalletHub, 2023; 3 WalletHub, 2022; 4 U.S. Census Bureau, ACS 1Y, 2021; 5 Defined as per capita GDP, U.S. Bureau of Economic Analysis, 2022;
